Human Stem Cells vs. Plant Stem Cells

With the combined efforts of biologists, geneticists, and clinicians, enormous progress has been made in the field of regenerative medicine and stem cell technology. Stem cells are one of the most promising advancements to come about in recent years, facilitating developments in ways that were inconceivable a few years ago. Novel pathological mechanisms have been […]

Read More >>

Dr. Russell Kern Interviewed for Neuro-Central Feature

Recently, Neuro Central’s Lauren Pulling had the opportunity to interview Russell Kern, PhD, Executive Vice President and Chief Scientific Officer of the International Stem Cell Corporation (ISCO) that is currently conducting the world’s first-in-human clinical study of neural stem cells in Parkinson’s disease patients and enrolling patients in Melbourne, Australia at the Royal Melbourne Hospital, with […]

Read More >>

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation’s Phase I Clinical Trial for the Treatment of Parkinson’s Disease

IRVINE, Calif., May 23, 2016 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation’s (OTCQB: ISCO) (“ISCO”) for its Phase I clinical trial in Australia for the treatment of moderate to severe […]

Read More >>

International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results

CARLSBAD, CA — March 31, 2016 – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015. “2015 was a […]

Read More >>

International Stem Cell Corporation to Raise $6.3 Million through a Private Placement to Fund Phase I Clinical Trial

CARLSBAD, CA. – (Marketwired – March 10, 2016), International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products , announced today it has entered into definitive agreements with two institutional healthcare investors and management for the private placement of $6.3 million of the Company’s convertible preferred […]

Read More >>

ISCO Signed a Clinical Service Agreement with the Florey Institute of Neuroscience and Mental Health

CARLSBAD, CA — (Marketwired) — 12/23/15 — International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial […]

Read More >>

ISCO Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson’s Disease

Regulatory submission (CTX) cleared for Phase I dose escalation trial in patients with moderate to severe Parkinson’s disease CARLSBAD, CA–(Marketwired – December 14, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission […]

Read More >>

ISCO Announces Launch Plans for New Nano-Compound Products

CARLSBAD, CA–(Marketwired – December 01, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season. The initial […]

Read More >>